Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Nov;96(6):E653-E659.
doi: 10.1002/ccd.28819. Epub 2020 Feb 25.

Early clinical experience with the straight design of Venus P-valve™ in dysfunctional right ventricular outflow tracts

Gareth J Morgan  1   2   3 , Kothandam Sivakumar  4 , Worakan Promphan  5 , Sebastian Goreczny  1   6 , Pimpak Prachasilchai  5 , Shakeel Qureshi  3
Affiliations
Multicenter Study

Early clinical experience with the straight design of Venus P-valve™ in dysfunctional right ventricular outflow tracts

Gareth J Morgan et al. Catheter Cardiovasc Interv. 2020 Nov.

Abstract

Objectives: To assess the initial procedural and short to medium-term experience with the straight design of the Venus P-valve™ (Venus MedTech, Hangzhou, China) in dysfunctional right ventricular outflow tracts (RVOT).

Background: The Melody™ valve (Medtronic, Minneapolis, Minnesota) has been the only percutaneous valve option for smaller RVOT conduits. The straight Venus P-valve™ may provide an alternative to the Melody™ valve.

Methods: Retrospective data collection of patient characteristics, procedural data, clinical and imaging follow-up of the straight Venus P-valve™.

Results: Nine patients (four female) with a mean age of 23.1 ± 7.5 years and a mean weight of 72.7 ± 29.4 kg underwent straight Venus P-valve™ implantation between 03/2014 and 06/2016. All patients had right ventricle-to-pulmonary artery conduits which were pre-stented before the valve implantation. All valves were deployed successfully without any significant procedural complications. During the mean follow-up of 24 ± 9.1 months, there were no valve related re-interventions or deterioration in valve performance. There was one case of insignificant, single wire frame fracture and no cases of endocarditis. The cohort demonstrated a reduction in pulmonary regurgitation and tricuspid regurgitation, which was sustained throughout the follow-up. Similarly the gradient across the RVOT tract did not significantly increase.

Conclusions: Implantation of the straight Venus P-valve™ has provided satisfactory short to mid-term results with high success rates and no complications and may be considered as an alternative option in patients with RVOT dysfunction.

Keywords: congenital heart disease; percutaneous intervention; transcatheter pulmonary valve.

PubMed Disclaimer

References

REFERENCES

    1. Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Perctaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet. 2000;356:1403-1405.
    1. Momenah TS, EI Oakley R, AI Najashi K, Khoshhai S, Al Qethamy H, Bonhoeffer P. Extended application of percutaneous pulmonary valve implantation. J Am Coll Cardiol. 2009;53:1859-1863.
    1. Zahn EM, Hellenbrand WE, Lock JE, McElhinney DB. Implantation of the melody™ transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit early results from the U.S. clinical trial. J Am Coll Cardiol. 2009;54:1722-1729.
    1. Kenny D, Hijazi ZM, Kar S, et al. Percutaneous implantation of the Edwards SAPIEN transcatheter heart valve for conduit failure in the pulmonary position: early phase 1 results from an international multicenter clinical trial. J Am Coll Cardiol. 2011;58:2248-2256.
    1. Demkow M, Biernacka EK, Spiewak M, et al. Percutaneous pulmonary valve implantation preceded by routine prestenting with a bare metal stent. Catheter Cardiovasc Interv. 2011;77:381-389.

MeSH terms

LinkOut - more resources